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THE AUSTRALIA (Hepatitis-associated) ANTIGEN
Christopher Smith, M .B ., C h .B ., M .R .C .P .E .
“ M ost great discoveries are accidental” 
Sir H enry D ale
“ Discovery comes to the mind prepared”  
Louis Pasteur
INTRODUCTION
T h e  accidental discovery of the Australia 
antigen ('HAA) in 1963 by Blum berg and his 
coworkers is a classical exam ple of biom edical 
serendipity. Its recognition not only stim u­
lated a substantial am ount of research into 
viral hepatitis, thereby adding considerably to 
our knowledge about this im portant disease, 
but has had far-reaching im plications in the 
understanding of several other hepatic and 
systemic diseases. Indeed, its discovery may 
well be seen in the future to have been the 
all-im portant breakthrough in attem pts at 
culture of the virus as a means of vaccine pre- 
partion for future prophylactic usage.
THE DISCOVERY OF THE ANTIGEN
B lum berg, a cytogeneticist working in the 
Philadelphia Institute for C ancer Research, 
was conducting a systematic study of the 
serum of patients who had received m ultiple 
blood transfusions. U sing a technique of 
double diffusion in agar gel (O uchterlony 
method) he searched for precipitating anti­
bodies to inherited donor serum protein anti­
gens, particularly those to low  density beta- 
lipoproteins. A  precipitating antibody was 
identified in the serum of a haem ophiliac 
patient which reacted with an antigen which 
was quite dissimilar from  lipoprotein antigens. 
T h is antigen was present in the serum of an 
Australian aborigine, and the term Australia 
antigen was coined ( 1, 2, 3,). T h is antigen 
is alm ost certainly identical to Prince’s SH- 
antigen (4), and to avoid confusion the term 
hepatitis-associated antigen (H AA ) is now con­
sidered by m any to be m ore appropriate (5).
It  was some time before it becam e apparent 
that the Australia antigen was closely related 
to, or m ight be located directly on, a hepa­
titis virus. It was found in the serum of some 
30 per cent of patients institutionalised be­
cause of D ow n’s syndrome (mongolism) but 
did not occur in out-patients with this disease 
or in hospitalised patients with other causes 
o f m ental retardation. In these institutional 
ised mongoloid patients antigenaemia was 
associated with chronic anicteric hepatitis, as 
shown by liver biopsy and elevated S .G .P .T . 
levels (6). T h e  antigen was isolated by 
density-gradient sedimentation, and under the 
electron m icroscope was found to be a particle 
of 200 A °  in diam eter with knob-like subunits 
of some 30 A °  on the surface. Agglutination 
of these particles occurred on addition of anti- 
H A A  antiserum. T h e  liver cells of patients 
whose blood contained the antigen was then 
shown to have striking fluorescent granules in 
or on their nuclei when fluorescent anti-H A A  
was added (7), a phenom enon not seen in 
patients w ithout hepatitis or in those who do 
not have the antigen in their blood (3). 
C lin ical hepatitis was then found to result in a 
high proportion of patients given transfusions 
of blood from donors who carried the Australia 
antigen (8). Epidem iological studies sugges­
ted that the antigen was an infective agent, 
and supported the conclusion that the Austrai- 
lia antigen was intim ately associated with a 
virus that caused hepatitis. Subsequent studies 
suggested that the antigen was associated with 
clinically different forms of hepatitis, the form 
depending on the im m une status of the 
patient (9). T h e  antigen was also shown
to b e  rare in N o rth  A m erica and the 
U n ited  K in gdom  (0.1 per cent) b u t was co m ­
m on in p eop le  livin g in the tropics (2-20 per 
cent). Indeed, these patients seem ed to  be 
susceptible to ch ron ic in fection  w ith  the hepa­
titis virus (10), a p o in t th at w ill be m ore fu lly  
discussed later.
THE NATURE OF THE ANTIGEN
T h e  A ustralia  antigen was show n by the 
B lum berg group to differ from  the serum beta- 
lipoproteins w hich  they had previously de­
scribed in th at it had a high m olecular w eigh t 
and contained proteins w ith  m in im al am ounts 
o f lip id . E lectron  m icroscopic studies of anti- 
gen-positive serum , prepared by sucrose den- 
sity-gradient centrifugation  and a negative- 
stain ing tech nique, revealed virus-like particles
(11). T h e se  particles w ere abou t 200 A °  in 
d iam eter w ith  knob-like subunits o f 30 A °  dia­
m eter. Som e had a central core w h ile  others 
w ere elongated their len gth  varying 
from  500 A °  to 2 300 A ° . T h e  
addition  of specific rabbit antiserum  to the 
A ustralia antigen resulted in agglutination  of 
the particles. T h e  unusual degree of pleo- 
m orphism  was the only  feature in com patib le  
w ith  firm accep tan ce o f the particles as viral 
in origin. N u cle ic  acid has, how ever, never 
been dem onstrated in these particles, another 
som ew hat unusual feature, alth ough it is pos­
sible that the virus contains little  or no nucleic 
acid. A  w ide variety o f particles can b e  de­
tected  in serum by electron m icroscopy and 
A ustralia antigen particles are so p leom or­
p hic that th ey  m ay only b e  recognised w ith 
confidence in th e  presence of tubular forms
(12). Sm all antigen particles seem to  pre­
dom in ate in acute hep atitis, w h ile  large par­
ticles and tubular form s occur in carriers of 
the antigen, or in patients w ith  ch ron ic hep a­
titis. C erta in ly , there is n ow  w ide acceptance 
that the presence of particles o f 22 A 0, w ith 
little  substructure, and those o f 4 2  A °  w ith 
a dense outer coat abou t 7 A ° across and an 
inner b o d y o f 28 A 0 in association w ith H A A . 
is in dicative o f infection  w ith  the S .H . virus. 
S ince the specific an tibody to  Australia an ti­
pen w ill cause clu m p in g o f both these parti­
cles (13) it  is now  generally agreed that th e  a r ­
ticles them selves con stitute  the antigen ) 14).
A lm eida and W a terso n  (13) have described 
three p a tte rns of A ustralia antigen as observed 
under the electron m icroscope in relation to 
clin ical features.
1. In th e  p atien t w ith  fu lm in an t hep atitis, 
large am ounts of an tibod y separate the 
aggregated particles;
2. in the p atient w ith  ch ron ic active 
hepatitis, unattached p articles o f antigen- 
w ere seen, togeth er w ith  im m un e com ­
plexes w ith  antigen excess; and
3. in sym ptom -free carriers o f the antigen, 
random ly distributed spherical and tubu­
lar particles w ere observed w ith ou t c lum p ­
ing by  antibody.
It has been suggested by D a n e  et al (1970) 
that the large (42 A ° )  particles are th e  virus 
itself, w h ile  the tubular form s are surplus virus 
coated m aterial (15). T h e se  particles have 
som e features in com m on  w ith  arborviruses. 
It has, how ever, been variously suggested that 
the virus associated w ith  the A ustralia antigen 
m ay b e  a variant o f the cow pea-chlorotic virus, 
or a m em ber o f th e  p icom avirus fam ily, w hich  
cause duck hepatitis. A lm eida and her col­
leagues have fu rth er suggested that the A u s­
tralia antigen  m ay be an aggregation o f protein 
subunits derived from  the virus (13, 16). Zu ck- 
erm an, w orkin g w ith  A lm eida, has described 
particles foun d on electron m icroscopy th at dis­
played the characteristics o f the coronavirus 
group, and suggested that the particles 
appeared to consist o f antigen-antibody Com­
plexes (17 , 18). M o re  recently  this group 
have reported th e  apparently successful pro­
pagation o f the serum  hep atitis virus in hum an 
em bryo liver organ cultures, confirm ing their 
results on electron m icroscopy. M aterial 
harvested from  these cultures has been suc­
cessfully passaged, so th a t the fu ll elucidation 
of the virus, and the antigen w ith  w hich it 
is inextricably associated, m ay n ow  not be far 
aw ay ( 19).
DETECTION OF THE ANTIGEN
T h e  earlier workers elicted  the presence of 
the A ustralia antigen in serum using the micro- 
O u ch te rlo n y  im m unodiffusion  tech n iq u e  (1). 
Since then, m ore sensative m ethods have b e­
com e available. T h e se  in clude co m p lem en t 
fixation, im m un oelectrophoresis, haem agglutin- 
ation , haem agglutination-in hibition, radio­
im m unoassay, and electron m icroscopy using 
negative-staining techniques.
T h e  im m unodiffusion  m eth od  is sim ple to 
perform , b u t n o t sensitive. C o m p lem en t fixa­
tion  is m ore sensitive, and is am enable to q uan- 
titative determ ination  of both  Australia a n ti­
pen and specific an tib o d y . Im m unoeleetro- 
osm oohoresis is a rapid and com paratively 
sim ple tech nique w hich is less sensitive than 
co m p lem en t fixation b u t  m ore sensitive than 
im m unodiffusion. H aem agglutination  and 
In cm aeglutin ation -in hib ition  are h igh ly  sen­
sitive for detection  of an tib o d y to the antigen.
Electron microscopy is relatively elaborate to 
perform, but is a rapid and sensitive method. 
Radio-immunoassay is about twice as sensitive 
as com plem ent fixation, while immunofluores­
cence is amenable to detection of the Australia 
antigen in liver biopsy specimens. T h e  more 
recently developed methods include an im­
m une adherence-haemagglutination technique 
which lends itself to automation, and a latex 
agglutination test which is simple and rapid 
to perform, and sensitive.
T h e  Australia antigen has been found, not 
only in serum, but in liver biopsy specimens, 
where it can sometimes be demonstrated by 
immunofluorescence when negative in the 
serum. Faecal antigens have also been des­
cribed (20, 28) while urinary spread seems 
probable, for chronic carriers of the antigen 
m ay excrete it in their urine. T h e antigen 
has also been detected in bile, and may well 
be present in saliva, as scrum hepatitis can 
apparently be spread by kissing.
PREVALENCE OF THE ANTIGEN
Com m unity studies have shown that the 
Australia antigen is rarely found in the healthy 
population of North America and the United 
Kingdom  (0.1 per cent), and is exceptionally 
rare here in those under 18 . In tropical coun­
tries, however, the antigen is found far more 
frequently in the serum of apparently normal 
people. Figures quoted by Blum berg (3) for 
these countries include Costa Ricans (2 per 
cent), Australian aborigines (2.1 per cent), 
Brazilians (2.5 per cent), M elanesians (3.6 per 
cent) Filipinos (4.8 per cent), Vietnam ese (6.3 
per cent), M icronesians (7.2 per cent), G han­
aians (9.5 per cent), Taiwanese 13  per cent 
and Peruvian Indians (20.2 per cent).
T h e Australia antigen is also commonly 
found in patients with acute myeloid leukae­
mia, and with acute and chronic lym phatic 
leukaemia. M ost of these patients, however, 
have received blood transfusions as part o f  
their therapy, and few have hepatitis. Patients 
with lepromatous leprosy also have an unusu­
ally high incidence of positivity in relation to 
their fellows in the com m unity and in com ­
parison with patients with tuberculoid leprosy. 
T h is is presumably due to their altered cellu­
lar im m unity, favouring persistence of the anti- 
sen, together with a high incidence of antigen 
in the community.
Patients on chronic renal haemodialysis pro­
grammes. who also have altered cellular im­
m unity due to their uraemia, and m ay in addi­
tion be receiving immunosuppressive therapy, 
have an usually high incidence of positivity in
comparison with other hospitalised patients 
often becom ing chronic carriers of the antigen 
after incidents of m ild hepatitis.
High carriage rates have more recently been 
reported in “ m ainline”  drug addicts in Europe 
and Am erica, figures of 7 per cent being recor­
ded in one recent survey.
T h e  association between Australia antigen 
and D ow n’s syndrome has long been recog­
nised, and was reported by Blum berg in 1967 
(2). Figures of between 27.7 and 35.1 per 
cent have been variously reported for mongol- 
oid patients in institutions. M any of these 
patients have histological evidence of chronic 
active hepatitis, and their age at tim e of ex­
posure seems to determine long-term antigen 
carriage. T h e  chronic carriage of the antigen 
in these patients m ay also be related to im ­
munological deficiency.
SERUM HEPATITIS
Although Blum berg and his workers recog­
nised that the Australia antigen was intim ately 
associated with a virus causing hepatitis and 
that its presence in serum was indicative of 
the presence of that virus (21), it  was not until 
later that the clear association of the Australia 
antigen with serum or long incubation period 
hepatitis was shown.
Prince (22) reported a close association be­
tween the Australia antigen and lone incuba­
tion period hepatitis in 1 968, calling the anti­
sen SH  or serum hepatitis antigen. It  is 
identical with the Australia antigen and is 
absent from the serum of patients with com­
mon source outbreaks of short incubation 
period infectious hepatitis. T h e  finding of 
Australia antigen in patients with presumed 
infectious hepatitis has been reported and is due 
to the diagnosis being made solely on clinical 
grounds.
U n equivocal evidence for the presence of two 
quite distinctive clinical, epidemiological and 
im m unological types of viral hepatitis was pro­
vided by the work of the Krugman 
group at W illow brook State School for 
m entally retarded children in Staten 
I sland. N ew  York (2 3 , 24). W hatever 
one may think of the ethics of these 
experiments —  and they certainly provoked a 
world-wide outcry —  the work was brilliantly 
conceived and m ethodically and scientifically 
done. B y infecting these children shortly after 
their admission to the school with serum from 
patients known to have infective and serum 
hepatitis and taken from these patients shortly 
before the developm ent of jaundice 
a considerable amount of clinical, bio-
chemical, and other data was collected. T h e  
trials were done with the acquiescence 
of the children’s parents and were defended 
on the grounds that viral hepatitis was endemic 
at the school and that the children, most of 
whom could not be toilet trained, would al­
most inevitably acquire hepatitis by the faecal- 
oral route while resident in the school. T h e 
experiments were condoned and sanctioned by 
committees set up in America to monitor 
human experim entation, and were conducted 
in accordance with the W orld  M edical Associ­
ation’s D raft Code of Ethics o n  human ex­
perimentation.
T h e  data accumulated during those studies 
has contributed im measurably to the under­
standing of viral hepatitis. T w o quite dis­
tinctive varieties of infectious hepatitis were 
shown to exist. O ne type resembled classical 
infectious hepatitis (IH ) and was characterised 
by an incubation period of 30-38 days, a rela­
tively short period of liver function test abnor­
m ality and a high degree of infectivity. T h e  
second type resembled serum hepatitis (SH) 
and was characterised by a longer incubation 
period, a more protracted and severe clinical 
and biochem ical upset and moderate infectiv­
ity. On reinfecting the patients it was shown 
that one attack of IH  protected the child from 
a second and that patients who had been 
given the SH  type were in no way immune 
from the IH  variety of infection. T h ey sub­
sequently showed also that IH  could be trans­
m itted parenterally as well as orally and SH  
orally as well as parenterally. T h e  mode of 
transmission did not affect the incubation 
period of the IH  virus, this being essentially 
the same after oral and parenteral exposure. 
T h e  incubation period for the SH  virus how­
ever was longer following oral than parenteral 
inoculation. T h ey  also showed that gamma­
globulin protected against the infectivity of IH  
but not against that of SH  serum.
T h e discovery of the Australia antigen 
allowed the Krugman group then to extend 
their studies using the antigen as a marker. 
T h ey tested 25,000 specimens of serum, col­
lected and stored during their earlier experi­
ments on 700 patients with viral hepatitis, for 
the Australia antigen. Th is showed that the 
Australia antigen was consistently present in se­
ra from patients with long incubation period 
hepatitis (SH) but was not present in sera 
from patients with short incubation period 
infective hepatitis (IH ). M oreover, the anti­
gen was detected earlier after a parenteral ex­
posure to SH  than to oral exposure, appearing
jaundice. T h e  antigen was also found to be 
two weeks to two months before the onset of 
transient in 65 per cent of the children given 
S H , lasting a mean of 49 days. It persisted 
for many months, however, in the remaining 
35 per cent of children. In addition, the 
children given SH  infection were im m une fol­
lowing re-exposure to S H virus one year later. 
T h eir observations amply confirmed that the 
Australia (hepatitis-associated) antigen was 
specifically related to serum and not to infec­
tive hepatitis and showed that if the antigen 
was present for more than four months it was 
likely to persist indefinitely. T h ey also 
showed that serum containing the antigen and 
obtained from patients who had never had 
overt hepatitis, was capable of causing serum 
hepatitis. Indeed, it has been shown that 
less than 0.001 ml. of serum containing the 
Australia antigen was infectious (25) although 
the severity of the resultant hepatitis may de­
pend on the dose of the antigen (26). Barker 
et al (1970) have also shown that the trans­
mission of serum hepatitis was associated with 
the administration of an H AA-positive plasma 
pool containing virus-like particles of approx­
im ately 20 A 0 diameter. Th is is further 
strong support for the hypothesis that the 
Australia antigen (H AA) is an integral part 
of the serum hepatitis virus.
SEOUELAE OF IN FEC TIO N  W IT H  
TH E AUSTRALIA AN TIG EN  
( 1)  Sources of Infection
In the clinical context, the classical mode of 
infection with the serum hepatitis virus and 
the Australia antigen is parenteral by the trans­
fusion of infected blood or blood products, or 
by contaminated equipm ent, especially needles 
or syringes.
T h e  increasing incidence of drug abuse ex­
poses larger numbers of the com m unity to 
potential syringe-borne infection. Close con­
tacts with addicts, who are not themselves 
“ m ainliners”  can contract the disease. It is 
probable on clinical grounds that kissing and 
sexual contact with antigen positive persons 
may well lead to serum hepatitis. It has, of 
course, also been shown in the W illowbrook 
experiments that the disease may be spread by 
the faecal-oral route. Hospital-acquired dis­
ease, for example in uraemic patients on 
chronic renal dialysis, may also spread to the 
community. Indeed, eases have been repor­
ted where the spouse of such a patient has con­
tracted a fatal serum hepatitis illness.
T h e  importance of mass screening of blood 
donors is apparent in this context, especially
as the antigen has been shown to have persis­
ted over 20 years in a patient who has remained 
apparently entirely well over that period (27). 
Shaving brushes, razors, toothbrushes, hairdres- 
sing implements, dental instruments and 
tatoo needles contaminated with Australia 
antigen positive blood have all been implica­
ted in the spread of serum hepatitis.
The identification of the Australia antigen 
in faeces (28) and urine and bile creates fur­
ther obvious possible sources for the spread of 
the disease.
(2) Consequences of Infection
This depends on the dose, virulence of the 
strain, previous exposure to the antigen, and 
the immune status of the individual. In the 
latter context, depression of cellular immunity 
is particularly important. The patient who 
is immunocompetent is likely to get severe or 
fulminant hepatitis, while the patient who is 
immunodepressed by disease or iatrogenically 
is likely to have mild hepatitis. The 
former patient, should he survive, will 
probably rid himself of the antigen within two 
months of the onset of clinical hepatitis. The 
immunodepressed or immunosuppressed 
patient is, however, likely to have mild hepa­
titis with persistence of the antigen, often in­
definitely. Some of this group will become 
apparently healthy long-term carriers of the 
antigen, while others may develop chronic 
active hepatitis that may proceed to cirrhosis. 
This has been well shown in the outbreaks of 
serum hepatitis in renal dialysis units. The 
patients tended to have mild hepatitis followed 
by persistent antigenaemia while the staff had 
severe and often fatal hepatitis, but cleared 
the antigen from their blood.
The Australia antigen is detectable in the 
scrum some weeks before there is subjective or 
clinical illness and may be detcted in the liver 
after recovery, when the patient is seronegative. 
Some antigen positive patients show allergic 
manifestations during the late incubation 
period or early in the phase of active hepatitis 
with urticaria, arthralgia, angioneurotic oede­
ma and sometimes migrainous headaches. This 
may be related to the presence of circulating 
immune complexes of Australia antigen, its 
antibody, and complement.
The antigen becomes demonstrable in the 
hepatic parenchymal cells at this stage and can 
be nicely shown by immunofluorescent or E M  
studies. The patient may then develop the 
fulminant picture, which is similar to that of 
acute massive necrosis from any cause. There 
is a high mortality rate in this group despite
intensive therapy with colomycin, lactulose, 
parenteral glucose, heparin and fresh frozen 
plasma followed by extracorporeal perfusion, 
or exchange transfusion. More often, how­
ever, the patient will recover after a protracted 
period of cholestatic jaundice. Most who are 
immunocompetent will clear the antigen with­
in four to ten weeks (29). These are the 
group, however, who run the risk of destroying 
their liver, presumably by a vigorous antigen- 
antibody reaction. M any will have no lasting 
hepatic damage, although some may proceed 
to chronic hepatitis of the mild persistent or 
even the severe aggressive varieties. Chronic 
persistent hepatitis often follows the classical 
attack of acute serum hepatitis, leading to cir­
rhosis, while chronic aggressive hepatitis tends 
to follow a mild or subclinical attack of antigen 
positive hepatitis. Certainly, cirrhosis is most 
likely when the Australia antigen remains 
positive after the acute attack. This persis­
tent antigenaemia is probably related to im­
munological defects, especially in cellular im­
munity. It is at least possible that the SH 
virus may gain in virulence by passage through 
patients who are immunosuppressed either by 
uraemia or by azathiprine (Imuran), cyclop­
hosphamide and antilymphocytic serum, 
causing very severe or fulminant hepatitis when 
an immunocompetent person is infected. This 
is, however, conjectural.
CELLULAR IMMUNITY AND THE 
ANTIGEN
It has been postulated that a complex series 
of interactions between the Australia antigen, 
the serum hepatitis virus and the immune re­
sponse of the host, both cellular and humoral, 
follows infection with HA A  positive material 
although immune complexes of H AA and anti­
body are important in producing some of the 
varied clinical manifestations that follow infec­
tion, the cellular immune response seems to de­
termine the severity and persistence of the as­
sociated liver damage. It has recently been sug­
gested that the competence of the cell medi­
ated (T-lymphocyte dependent) immune sys­
tem determines whether the infection is self- 
limiting or persists with varying degrees of 
damage (30).
Krugman and his associates showed that in­
oculation of children with standard prepara­
tions of Australia antigen-positive scrum re­
sulted in a spectrum of clinical outcomes (24). 
Although transient antigenaemia was usual in 
association with either overt or anicteric hepa­
titis, persistence of the antigen could occur in 
association with either chronic active hepatitis,
or without apparent disease. T h e  actual 
course is dependent on m any variables, includ­
ing genetic predisposition, im m une com pet­
ence, the virulence of the virus, its dose and 
mode o f transmission. T h e  host response to 
the infective agent is, however, probably all- 
im portant in determ ining the clinical course 
followed by the individual patient.
A lthough the presence of im m une com ­
plexes of HAA correlate poorly with the de­
gree of liver damage, deposition of these com ­
plexes may play a role in th e developm ent of 
the serum-sickness like syndromes which some­
times precede serum hepatitis. O nly a mild 
persistent hepatitis is seen in the presence of 
com plexes in HAA positive polyarteritis, while 
acute and chronic hepatitis can occur in 
patients with agam m aglobulinaem ia. Im ­
m une com plex disease is therefore unlikely to 
be the m echanism  by which HAA causes liver 
cell damage (30).
It is more probable that liver cell necrosis 
is related to the cellular im m une response of 
the host to the infecting agent. This res­
ponse is controlled by thym us-dependent lym ­
phocytes, and variations in their function 
could determine the clinical course that fol­
lows infection with HAA positive material. 
T h is is supported by the fact that im pairm ent 
of the cellular im m une systems results in mild 
hepatitis after HAA infection —  with persis­
tence of the antigen. People who are im- 
m unologically normal, however, develop 
severe hepatitis when infected, but clear the 
antigen rapidly from  their blood (3). Persis­
tence of the antigen is seen frequently in 
patients with impaired T-lym phocyte function 
(lym phoproliferative disorders, lepromatous 
leprosy, chronic lym phatic leukaemia). T h e  
high frequency of antigen in m ongolism m ay 
also be related to an abnorm al im m unological 
status.
D udley et al (30) have suggested that the 
Australia antigen, on gaining entry to the body, 
comes into contact with susceptible cells —  
possibly in the liver. Here it proliferates, pro­
ducing further infective particles plus excess 
virus coat material, both o f which are released 
from the cell w ithout having caused cell nec­
rosis. D uring transit out of the liver cell anti­
gens specific for the infective agent becom e 
incorporated in the surface m em brane of in­
fected cells. T h e  circulating foreign antigens 
are then recognised by im m unocom petent T- 
lym phocytes which proliferate to produce a 
num ber of sensitised lym phocytes. These 
then recognise and react with the antigens
on the surface of infected liver cells. T h is 
lym phocyte/antigen interaction results in des­
truction of the infective agent, and necrosis 
of the liver cell. M odification of this pattern 
can explain the various forms of Australia anti­
gen positive liver disease.
It  follows from this postulate that, in the 
presence of a normal im m une response the 
patient's T-lym phocytes will react in this m an­
ner, leading to extensive liver cell necrosis —  
but with clearance of the antigen, i.e. the in­
fective agent. I f  all the liver cells are involv­
ed, severe fulm inant hepatitis w ill result. I f  
few cells are infected, the hepatitis w ill be mild 
or subclinical. T h e  outcom e, therefore, with 
normal im m unological status, is fulm inant 
hepatitis, or com plete recovery. Conversely, 
if the patient’s im m unological state is abnor­
mal, little or no liver damage will result, but 
the patient would becom e a healthy antigen- 
positive carrier. An intermediate course 
would likewise result in a m ild hepatitis fo l­
lowed by continuing liver cell dam age and per­
sistent antigenaem ia (30). It follows from 
this hypothesis that immunosuppression will 
m odify the clinical course after HAA infection 
the therapeutic possibilities of this being offset 
by the likelihood of producing persistent anti­
genaemia.
CYTOPLASMIC LOCALISATION OF 
THE ANTIGEN IN LIVER
Recently, im m unofluorescent and electron 
microscopic techniques have demonstrated the 
Australia antigen in the cytoplasm of hepatocy- 
tes. Haynes et al (14) have shown hepatocy- 
tes. in antigen sero-positive patients to contain 
characteristic particles with m em brane bound 
cytoplasm ic vesicles. T h e  appearances of 
these particles was sim ilar to that of the Aus­
tralia antigen particles found in the serum. 
T w o sizes of cytoplasm ic particles were obser­
ved, with average diameters of 26 and 46 A ° . 
Particles o f both sizes often had a m em brane­
like outer com ponent and a m oderately elec­
tron-dense inner com ponent. T h ey  differed 
in both size and structure from the m ainly 
intranuclear particles described b y  previous 
authors (3 1).
Although a direct connection between the 
two types o f particles described above has yet 
to be established, it seems likely that the diff­
erent types are related to stages in the develop­
m ent o f the serum hepatitis virus. It  has 
been shown that there is apparent intranuclear 
replication o f 22 A °  particles, with consider­
able disruption o f the nucleus, and sometimes 
also with cytoplasm ic replication, occasionally
with the production of rather different parti­
cles within the cytoplasm ic vesicles. Others 
have shown no intranuclear replication or 
damage, but enormous production of particles, 
within the cytoplasm , of the larger type —  and 
a much greater degree of cytoplasmic damage. 
W hether these two situations represent differ­
ent stages of a single process or arc alternative 
manifestations of infection by the S H virus is 
uncertain. It  seems unlikely, however, that 
either one could lead directly to the other. 
Another possibility is that they arc related to 
the imm unological status of the patient (14). 
CHRONIC ACTIVE HEPATITIS 
(C.A.H.) AND CIRRHOSIS 
T h e  remarkable specificity of the Australia 
antigen for serum hepatitis and chronic active 
hepatitis in comparison to other forms of liver 
disease suggests that persistence of the antigen 
may be aetiologically important in some cases 
of chronic active hepatitis and cirrhosis.
Chronic active hepatitis is characterised by 
a prolonged course and the presence of persis­
tent hepatic inflammation with fibrosis which 
may progress to cirrhosis. Som e patients de­
velop polyserositis, hypergammaglobulinaemia, 
and positive serum antinuclear factors and 
even L .E . cells. T h e  pathogenesis of C.A.H. 
is unknown, but m ay have its origins in infec­
tion with the Australia antigen, superimposed 
upon primary, or com plicated by secondary 
imm unological factors (32). Although one 
study showed an association with H A A , several 
others have failed to do so. Som e reports have 
shown progression, on liver biopsy, from 
serum hepatitis to cirrhosis, so that the H A A  
may have a role to play in some cases of C.A.H . 
and cirrhosis. In these cases it seemed pro­
bable that persistent viral infection, as judged 
by antigenaemia, has contributed to the path­
ogenesis of C.A.H. O ther cases m ay conceiv­
ably be initiated by infection with the SH  
virus and H A A , but be perpetuated by some 
other mechanism, possibly auto-immune, after 
clearance of the antigen (12). Zuckerm an et 
al (33) have, however, detected particles by 
electron microscopy (EM ) in the serum of a 
patient with C.A.H. and cirrhosis whose serum 
was H A A  negative, so that the apparent ano­
maly may lie in the sensitivity of present 
methods of testing for antigen.
P R IM A R Y  B IL IA R Y  C IR R H O S IS  A N D  
T H E  A N T IG E N  
Particles identical to those associated with 
the Australia antigen were found by E M  in 
the sera of 1 1  out of 12  patients with primary 
biliary cirrhosis. Antigen and/or antibody to
Australia-antigen was also found in 9 out of 
10  of these cases by sensitive immunological 
methods (34). These findings remain to be 
confirmed, but the suggestion is that the liver 
damage in primary biliary cirrhosis may be due 
to either continuing replication of the SH  
virus, or be the result of the patient’s immune 
response to persistent antigenaemia. T h e  
presence of autoim m une (smooth muscle and 
anti-mitochondrial) antibodies in this condi­
tion has led to the suggestion that the condi­
tion is either due to or associated with abnor­
mal im m une reactivity, the trigger possibly be­
ing the SH  virus.
HEPATOCELLULAR CARCINOMA 
AND THE ANTIGEN  
There has recently been worldwide interest 
in the possible oncogenic properties of the SH  
virus and H A A . In Uganda (35) 40 per cent 
of patients with hepatocellular carcinoma had 
the Australia antigen in their blood. These 
workers found a tendency for H A A  positive 
individuals with hepatocellular carcinoma to 
be alpha-fetoprotein positive, and to have 
underlying cirrhosis of the posthepatic type. 
Young patients tended to be H A A  positive 
more frequently than the older ones who were 
often alpha-fetoprotein negative. T his data 
certainly suggests an association between per­
sistent antigenaemia and the pathogenesis of 
hepatoma —  at least in Uganda, especially 
as only 4 of their 122  controls (3 per 
cent) were antigen positive. It is certainly 
tem pting to speculate that antecedent viral 
hepatitis plays a causative role in the neoplastic 
transformation of the liver cell. Other work­
ers have lent support to this theory, with 
marked differences across the globe. In Sing­
apore 3 per cent of 1 1 4  patients with hepato­
mas were H A A  positive, in Japan 5 per cent 
of 19 , in India 63 per cent of 1 1 ,  and in Twai- 
wan 80 per cent of 55. Alternatively, in 
South Vietnam  H A A  was not found in any of 
the patients with hepatoma that were studied, 
but was present in 4 per cent of their controls! 
(36)
POLYARTERITIS AND AUSTRALIA 
ANTIGEN 
A  most interesting survey of 1 1  patients with 
biopsy-proven polyarteritis nodosa showed 4 of 
them to be Australia antigen positive. T h e  
four H A A  positive patients exhibited 
a typical polyarteritis syndrome, but 
differed from the antigen negative 
patients in having evidence or m ild hepatic 
damage. T h e  presence of circulating im ­
mune complexes in the sera of 3 of the 4 anti-
gen positive patients was demonstrated by sero­
logical, ultraccntrifugal, and E M  studies, and 
were shown to be composed of Australia anti­
gen and imm unoglobulin. Immunofluores- 
cent studies of tissue from one of the patients 
revealed deposition of Australia antigen, IgM  
and B 1 C  in blood vessel walls. T h e  sugges­
tion is that the syndrome of diffuse vascular 
damage observed in these patients was 
due to deposition of im m une com­
plexes in the blood vessel walls, and that these 
deposits were composed of Australia antigen, 
homologous IgM  antibody, and com plem ent 
components (37).
THE HUMAN BEING AND HIS 
AUSTRALIA ANTIGEN
During the recent tragic Edinburgh serum 
hepatitis outbreak, the com m unity in general 
and hospital staff in particular came face to 
face with a new and terrifying reality —  inocu­
lation with antigen positive material m ight 
herald a fatal illness. This transformed 
people, and created problems that are only 
now being fully realised as the immediate 
danger seems past. Patients were sometimes 
treated as were lepers, and m any are still aware 
of being ostracised, despite a long-standing 
negative Australia antigen. M any doctors 
and nurses did, however, behave in a manner 
that does them very great credit, and signs are 
around that medicine, in its broadest sense, is 
com ing to terms with the discovery that Blum- 
berg fell upon quite by accident almost a de­
cade ago. He could hardly have realised then 
that he had, in truth, perhaps created more 
problems in his discovery than have been 
solved by the now clear cut delineation of the 
two forms of viral hepatitis by the recognition 
of the Australia antigen.
“ Knowledge comes, but wisdom lingers.”  
Lord Tennyson
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